{
  "docId": "019de074-0bfb-75bc-a2eb-54d60d88aadd",
  "docSlug": "2fd96f096e3a949c3b11bf5955245231",
  "documentTitle": "OmniAb | Investor Conference Presentation Deck | 27 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 27,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses two pie charts to illustrate the expansion of the partner program pipeline over time.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-0bfb-75bc-a2eb-54d60d88aadd/15",
  "deckHref": "/decks/019de074-0bfb-75bc-a2eb-54d60d88aadd",
  "deckJsonHref": "/decks/019de074-0bfb-75bc-a2eb-54d60d88aadd.json",
  "deckAnchorHref": "/decks/019de074-0bfb-75bc-a2eb-54d60d88aadd#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.68,
        "x": 0,
        "y": 0.74
      },
      "kind": "callout",
      "text": "Substantial progress in all phases, increase in discovery programs expected to feed growth in new clinical programs and future approvals",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a93518e9-0f32-48f3-b1f2-0432d3cf0d94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.18,
        "y": 0.4
      },
      "kind": "chart",
      "text": "2016 partner programs",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f91f88e-0806-452a-994f-8f54f734bfa1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.25,
        "x": 0.065,
        "y": 0.35
      },
      "kind": "chart",
      "text": "2022 partner programs",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "805ecb26-ec26-4f1f-adb4-cfaddb285c53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "(1) Estimated at the time of acquisition of OMT (2) In August 2022, our partner Jansen received marketing approval in the EU for teclistamab; and in October of 2022, Janssen received accelerated approval for teclistamab by the US FDA",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43483fd7-a2df-4d18-83da-9f887842565e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Growth of Partner Programs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24757175-06ba-42c4-a6fa-d0bf7907807e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "PROGRESSION AND PERFORMANCE IN PROGRAMS BY STAGE OF DEVELOPMENT",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97662ec4-1fe0-4469-b5cb-9dcbc5bc1f02",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "3595fe0a-73dc-48f0-a62e-390dd8b47d4b",
      "evidence": "Substantial progress in all phases, increase in discovery programs expected to feed growth in new clinical programs and future approvals",
      "confidence": 0.7
    },
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "489e33dc-81df-4577-8ea9-906b0c2e6016",
      "evidence": "chart/pie: 2016 partner programs, chart/pie: 2022 partner programs",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "caace6ce-c6fa-4956-b413-4e47a2219077",
      "evidence": "Comparison of 2016 and 2022 data to show growth and progression.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}